HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mutual Alleges Mucinex Monopoly In Extended-Release Guaifenesin

This article was originally published in The Tan Sheet

Executive Summary

Mutual Pharmaceutical alleges in an antitrust suit that RB attempts to monopolize the extended-release guaifenesin OTC category with its Mucinex product. The suit says Mutual has lost “tens of millions” due to RB's failure to honor a contract to supply an “authorized generic” of the product.

You may also be interested in...



Perrigo Sets Generic Mucinex Launch After Patent Claim Decision

The private labeler clears a Reckitt Benckiser legal hurdle and will launch generic Mucinex (guaifenesin) by April. Watson has filed ANDAs for three Mucinex products and could be a good strategic partner for Perrigo, an analyst suggests.

Adams Reinforces Mucinex Patents In Settlement Agreement With Mutual

A settlement agreement granting United Research Labs/Mutual Pharmaceuticals a conditional license for certain guaifenesin products could help Adams Respiratory Therapeutics fend off other potential generic competition for its Mucinex brand

P&G Health, Hygiene Brands Ride Consumer ‘Trust’ To Sales Growth Amid Pandemic Uncertainty

“There’s a heightened need for products that deliver against health, hygiene and clean home concerns and a willingness to spend just a little bit more to ensure that I’m using a product that I know and trust,” says CFO Jon Moeller 

Topics

Related Companies

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel